Meeting
2022 ASCO Annual Meeting
Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).
Presenter
Herve Lena
Centre Hospitalier Universitaire de Rennes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
Including the Excluded: Advancing Care for All Patients With Lung Cancer
Track
Lung Cancer,Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03351361
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9011)
DOI
10.1200/JCO.2022.40.16_suppl.9011
Abstract #
9011
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate 214 trial.
Speaker: Nizar M. Tannir, MD, FACP
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
Speaker: Nizar M. Tannir, FACP, MD
Videos & Slides
2019 ASCO Annual Meeting
Chair
Speaker: Gary Walter Unzeitig, MD
Videos & Slides
2017 ASCO Annual Meeting
Efficacy of the Addition of Cisplatin to Single-Agent First-Line Chemotherapy in Elderly Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Joint Analysis of the Multicenter, Randomized Phase III MILES-3 and MILES-4 studies
Speaker: Cesare Gridelli, MD